Tempus AI (TEM) Stock Rockets 24% Following Merck-Moderna Cancer Vaccine Breakthrough

Key Highlights

• TEM shares climbed approximately 24% following encouraging Phase 3 trial results from Merck and Moderna’s cancer vaccine collaboration
• The positive clinical data enhanced the strategic value of Tempus AI’s pending $1.5 billion Personalis acquisition, which supplies gene-sequencing technology for Moderna’s oncology program
• The company achieved its maiden quarterly GAAP net profit of $5.6 million in Q2 2026, accompanied by 22% revenue growth to $382.5 million
• More than 26% of the company’s outstanding shares are held short, creating conditions for an amplified upward price movement as traders covered positions
• Wall Street maintains a Moderate Buy rating on TEM shares with a consensus target price of $62.15

Shares of Tempus AI experienced a dramatic rally on Wednesday, climbing nearly 24% to approximately $59.64, driven by breakthrough Phase 3 clinical trial data from the Merck-Moderna cancer vaccine collaboration.

Tempus AI, Inc., TEM

The market reaction was swift and substantial. Tempus AI’s planned $1.5 billion acquisition of Personalis suddenly appears far more strategic. Personalis provides critical gene-sequencing capabilities that form the foundation of Moderna’s cancer vaccine development efforts. With a successful Phase 3 trial now on record, the acquisition’s value proposition strengthened considerably.

During Wednesday’s session, TEM reached an intraday peak of $59.04 before climbing even higher. The stock now trades significantly above its 52-week bottom of $40.77.

This surge isn’t solely attributable to a single catalyst. The company has accumulated multiple positive developments over recent weeks.

On July 30, Tempus AI announced its inaugural quarterly GAAP net profit of $5.6 million. This marked a dramatic turnaround from the $42.8 million loss recorded in the corresponding period one year prior.

The company generated $382.5 million in revenue, representing a 22% year-over-year increase. Management subsequently elevated its full-year 2026 revenue forecast to between $1.595 and $1.605 billion, while projecting Adjusted EBITDA near $65 million.

Heavy Short Interest Amplifies Rally

Over 26% of Tempus AI’s available float remains sold short. This elevated short interest transforms positive momentum into accelerated gains. As shares advance, short sellers must purchase stock to close their positions, creating additional buying pressure that further propels the price upward.

On August 4, a peer-reviewed study in Nature Medicine confirmed the effectiveness of TEM’s PRISM2 artificial intelligence platform for accurate cancer diagnosis and patient outcome prediction. This provided third-party scientific validation for the company’s fundamental technology.

Just two days afterward, on August 6, Tempus AI revealed a strategic collaboration with CellCarta, establishing Tempus as a commercial laboratory partner in CellCarta’s oncology companion diagnostics ecosystem.

The company’s data licensing segment continues expanding rapidly. Tempus reported a 36% year-over-year surge in data licensing agreements with pharmaceutical companies including Merck and Gilead.

Wall Street Perspective

Broader equity markets provided a supportive environment. The S&P 500 advanced 0.4% while the Nasdaq gained 0.1% on Wednesday, though these moves pale in comparison to TEM’s performance.

Wall Street analysts maintain a Moderate Buy consensus recommendation on TEM stock, reflecting eight Buy ratings and seven Hold ratings issued over the trailing three months. The average analyst price target stands at $62.15.

Prior to Wednesday’s explosive rally, TEM shares had already appreciated 8% during the previous three-month period.

The $62.15 consensus price target suggests approximately 4% additional upside potential from current trading levels.